Positive

From Nasdaq: 2025-06-30 05:05:00

Over the past year, Apple (NASDAQ: AAPL) and Amgen (NASDAQ: AMGN) have faced challenges. Apple is concerned about potential tariffs impacting its business, while Amgen faced a setback with a clinical trial. Despite this, both stocks are still worth investing in for the long term.

Apple manufactures abroad, mainly in China, where potential tariffs could increase costs and impact earnings. However, the company’s strong free cash flow and brand power could help mitigate these challenges. With a growing services segment and cash for investments, Apple remains a solid long-term investment option.

Amgen is working on a promising weight management medicine, MariTide, despite a recent setback. The medicine’s monthly dosing schedule and robust financial results are positive indicators for the company. With a deep pipeline and a history of strong dividend growth, Amgen remains a solid choice for long-term investors.



Read more at Nasdaq: 2 Dividend Stocks to Buy on the Dip and Hold Forever